{{Rsnum
|rsid=854547
|Gene=PPP1R9A
|Chromosome=7
|position=95294544
|Orientation=plus
|GMAF=0.4702
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=PPP1R9A
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 37.2 | 48.7 | 14.2
| HCB | 13.9 | 47.4 | 38.7
| JPT | 7.1 | 44.2 | 48.7
| YRI | 4.8 | 52.4 | 42.9
| ASW | 17.9 | 42.9 | 39.3
| CHB | 13.9 | 47.4 | 38.7
| CHD | 9.2 | 45.9 | 45.0
| GIH | 42.6 | 44.6 | 12.9
| LWK | 10.1 | 33.0 | 56.9
| MEX | 30.4 | 46.4 | 23.2
| MKK | 16.7 | 48.7 | 34.6
| TSI | 51.0 | 38.2 | 10.8
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs854547
|Name_s=
|Gene_s=PPP1R9A
|Feature=
|Evidence=PubMed ID:18615156
|Annotation=This variant is significantly associated with the efficacy of anti-TNF treatment in rheumatoid arthritis (Adjusted P-value: 0.000006; OR: 3.6 (1.5, 9.3)). The study is a genome-wide association study using the Illumina HapMap300 SNP chip on 89 RA patients prospectively followed after beginning of anti-TNF therapy.
|Drugs=adalimumab; etanercept; infliximab
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA162928825
}}

{{PMID Auto
|PMID=20423481
|Title=Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs854547
|overall_frequency_n=57
|overall_frequency_d=128
|overall_frequency=0.445312
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=52
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}